The Estée Lauder Companies Highlights Key Epigenetics & Multi-Ethnic Translational Clinical Research at 33rd IFSCC Congress
NEW YORK, Oct. 12, 2023 /PRNewswire/ -- The Estée Lauder Companies Inc. (ELC) (NYSE: EL) shared its latest clinical research findings in an invited keynote address and podium presentation at the 33rd International Federation of Societies of Cosmetic Chemists (IFSCC) Congress, held in Barcelona, Spain, in September. Nadine Pernodet, PhD, Senior Vice President, Bioscience, ELC, and Estée Lauder brand Lead Scientist, addressed innovation in the beauty industry in a lecture entitled, "Harnessing Epigenetics: from Anti-Aging to Age Reversal." Mei Yu, MD, PhD, Executive Director, Clinical Translation, Global Clinical & Consumer Science, Global R&D, ELC, presented a translational clinical study titled, "Development and validation of post-inflammatory hyperpigmentation (PIH) model in multi-ethnicities using different induction methods."
- Nadine Pernodet, PhD, Senior Vice President, Bioscience, ELC, and Estée Lauder brand Lead Scientist, addressed innovation in the beauty industry in a lecture entitled, "Harnessing Epigenetics: from Anti-Aging to Age Reversal."
- Mei Yu, MD, PhD, Executive Director, Clinical Translation, Global Clinical & Consumer Science, Global R&D, ELC, presented a translational clinical study titled, "Development and validation of post-inflammatory hyperpigmentation (PIH) model in multi-ethnicities using different induction methods."
- She also explained that, with the right technologies, understanding the positive and negative epigenetic signals provides the ability to reverse skin aging.
- This body of research is central to the ongoing development of approaches that enable innovations to shift from anti-aging to age reversal.